Inflammatory Bowel Diseases

CollPlant Issues Letter to Shareholders

Retrieved on: 
Thursday, February 15, 2024

Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.

Key Points: 
  • Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.
  • In June of last year, we announced the achievement of an important milestone under this collaboration which triggered a $10 million payment from AbbVie to CollPlant.
  • Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on product sales.
  • In the second quarter of 2023, CollPlant hired a dedicated expert to lead our Environment, Social and Governance (ESG) effort.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001

Retrieved on: 
Tuesday, January 23, 2024

Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.

Key Points: 
  • Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.
  • “We are entering the new year with positive momentum in Enthera’s corporate and clinical evolution with Lisa’s appointment as CEO and important progress with Ent001.
  • We are thrilled to have her join as CEO,” said Silvano Spinelli, Chairman of the Enthera Board of Directors.
  • Based on this, Enthera has initiated a multiple ascending dose (MAD) Phase 1b clinical trial in patients with moderately to severely active UC.

New Study Shows SonarMD Drives 10X Reduction in Hospital Admissions and Emergency Visits Related to IBD

Retrieved on: 
Friday, January 26, 2024

CHICAGO and LAS VEGAS, Jan. 25, 2024 /PRNewswire/ -- Technology-enabled patient engagement leads to 10 times fewer hospital admissions and emergency department (ED) visits among patients with inflammatory bowel disease (IBD), according to new research presented at the seventh annual Crohn's & Colitis Congress®, a meeting convening the IBD experts to transform patient care. This finding underscores the importance of proactive patient engagement as the foundation for population health.

Key Points: 
  • The study examined claims data of over 1,000 patients with IBD between January 2022 and December 2022.
  • Eighty percent (939 patients) were enrolled in SonarMD's program and 20% (234 risk-matched patients) were not enrolled during the study period.
  • Researchers measured disease-related ED visits, inpatient hospital admissions and the use of therapeutics, including biologics.
  • SonarMD helps practices overcome the first challenge of managing patients with complex chronic disease — engagement," said Beth Houck, CEO of SonarMD.

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Retrieved on: 
Wednesday, December 27, 2023

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.

Key Points: 
  • The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.
  • Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement.
  • The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases (IBD).
  • Intellectual property for niclosamide formulations governing composition of matter and methods of use extends beyond 2040.

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Friday, November 24, 2023

GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.

Key Points: 
  • GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.
  • GSK becomes eligible for a low single digit royalty from Sosei Heptares on net sales of GSK4381406 should it become commercially available.
  • Sosei Heptares’ strategy is to advance novel or best-in-class products through early clinical development before seeking a partner to develop and commercialize in major markets.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “We are delighted at the prospect of regaining ownership of GSK4381406 from GSK.

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Retrieved on: 
Friday, November 10, 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.
  • Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic expansion.
  • Note regarding the Idorsia transaction: the quarter ended 30 September 2023 (Q3 2023) is the first period in which the Group has consolidated the financial results of Idorsia’s former Japanese and South Korean businesses.
  • Revenue totalled JPY 5,474 million (US$39.6 million*), a decrease of JPY 3,167 million (US$27.9 million) vs. the prior corresponding period.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline

Retrieved on: 
Monday, November 6, 2023

Inotrem , an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.

Key Points: 
  • Inotrem , an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.
  • After initial support in December 2022, continuation of funding follows a thorough review of Inotrem’s interim data, successfully supporting the proof of concept of the company’s antibody program (INO-02).
  • This program targets the TREM-1 pathway for Inflammatory Bowel Disease (IBD) and develops a biomarker-based personalized approach to identify the patients most likely to benefit from the treatment.
  • The Crohn’s & Colitis Foundation, the leading nonprofit organization with the mission of curing Crohn’s disease and ulcerative colitis, decided to continue funding based on Inotrem’s successful achievement of the planned interim milestones.